Abstract Body

Background

Long-acting injectable pre-exposure prophylaxis (PrEP), including Lenacapavir, offers an opportunity to accelerate HIV incidence declines in southern and eastern Africa. Given constrained HIV budgets, competing needs for health resources, and high product and delivery costs, prioritization strategies are needed to maximize HIV prevention impact and deliver value with limited health resources. 

Methods

We used district-level estimates of HIV incidence and at-risk population sizes from the Naomi model published by UNAIDS to estimate the potential health impact and cost-effectiveness of Lenacapavir in 837 districts across 11 of the highest-burden countries in eastern and southern Africa. We evaluated the impact of universal (PrEP offered to all) versus risk-prioritized Lenacapavir delivery in different geographies by sex and age. We calculated the number needed to treat, infections averted, cost per disability-adjusted life year (DALY) averted, and threshold price at which Lenacapavir becomes cost-effective (at <$500/DALY), assuming an average $10,000 lifetime treatment cost and 20 DALYs incurred per HIV infection. We conducted sensitivity analyses for heterogeneity in risk of those most likely to uptake PrEP, looking specifically at districts across South Africa.

Results

In high HIV-incidence districts of southern Africa, Lenacapavir was cost-effective at ~$130 per person-year (py), but much lower costs were required for cost-effective delivery in lower-incidence regions (<$50/py). Focusing provision in the highest-incidence quintile of districts (20% of the population) could avert ~50% of new infections. Assuming Lenacapavir users have >2-fold higher HIV risk than the population average, a universal offer strategy to women 15-24 in South Africa was cost-effective across almost all districts. District-level cost-effectiveness maps identified settings where universal versus risk-prioritized provision would maximize impact for a given budget.

Conclusions

Marked heterogeneity in HIV incidence across districts and populations drove large differences in threshold cost and health impact of Lenacapavir provision across settings; the highest HIV incidence districts could cost-effectively deliver Lenacapavir at higher costs than low incidence districts. Streamlined PrEP delivery strategies with universal offer and user self-selection in high-incidence regions can achieve high impact and cost-effectiveness. 

Table or Figure